https://layoffcheck.com/companies/freenome Layoff and WARN notices reported for Freenome. en-us https://layoffcheck.com/companies/freenome#2024-04 https://layoffcheck.com/companies/freenome#2024-04-851 Tue, 23 Apr 2024 12:00:00 GMT Freenome cut just over 100 jobs, about 20% of its roughly 530-person staff, on April 23, 2024, weeks after clinical trial data for its colorectal cancer blood test came in below expectations. Results showed sensitivity rates trailing both Exact Sciences' Cologuard and Guardant Health's Shield test; Baird analysts described the data as "lackluster." The South San Francisco biotech said it was "restructuring its organization to align with strategic priorities" and to preserve resources for the long term. The cuts spanned multiple job functions. Freenome had raised $254 million in February 2024, led by Roche with participation from Quest Diagnostics, bringing its total funding to $1.3 billion since its 2014 founding. The company said transitional support would be provided to affected workers but did not specify terms.